Dear Participants,

We are delighted to announce the 22nd World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC), scheduled to be held from December 12-14, 2024. We are excited to invite you to participate in this prestigious event as presenters of abstracts and contributors to scientific discussions.

• As part of our appreciation for your valuable contributions, accepted abstracts will receive a 50% discount on in-person, all-access registration. However, please note that on-demand-only and one-day-pass registrations will be available at regular prices.
• Abstracts of exceptional quality will be selected for oral presentation during the meeting. The committee may also consider Late Breaking Abstracts for oral presentation in special cases. Only the highest-ranking abstracts submitted by participants who have registered for full access (in-person + on-demand) will be eligible for the Oral Abstract Presentation and the awards.
• Accepted abstracts submitted by registered participants will have the opportunity to present their posters at the Abstract Hall. Furthermore, all accepted abstracts from registered participants will be published in the journal "Metabolism," with Dr. Christos S. Mantzoros serving as the Editor-in-Chief.
• To encourage academic excellence, the top 6 abstracts will receive awards.

Abstract Submission & Topics: Abstracts should focus on clinical or basic science aspects of insulin resistance in fields such as diabetes, obesity, and cardiovascular disease. Investigations of pathophysiology and effects on key metabolic centers, such as the beta cell, adipocyte, gut, and brain, are of particular interest. Studies related to inflammation, endothelial or other vascular dysfunction and multi-hormonal aspects of obesity will also be considered. Clinical topics may encompass insulin resistance in relation to obesity, diabetes, hypertension, dyslipidemia, cardiovascular disease, renal disease, gonadal dysfunction, liver disease (NAFLD), malignancy, and sleep disorders such as obstructive sleep apnea.

Abstract Poster Presentations: Accepted abstracts may be submitted for a virtual poster presentation. Authors or presenters selected for virtual poster presentations must register for the Congress.

Abstract Oral Presentations: Four of the highest-ranking abstracts will be chosen for the Abstract Oral Presentation Session. Authors of winning abstracts will present their research findings in a 10-minute presentation, followed by a 5-minute Q&A session. If selected, authors are required to register for the meeting and prepare a PowerPoint presentation.

Top Abstract Awards: The highest-ranking abstracts will receive awards at different levels: Gold, Silver, Bronze, and honorable mentions. Award recipients will be chosen from the Abstract Oral Winners.

Important Information:

1. Submission period for late-breaking abstracts is from November 11 tto 25, 2024.
2. Deadline for submission is November 25, 2024 at 11:59 PM, Pacific Standard Time. 
3. Abstracts and scientific material presented at the conference must not have been published or presented prior to December 12, 2024.
4. Encore abstracts are accepted under special circumstances. Make sure to identify your abstract as an encore if it was published or presented in a different conference. Please note that Encore abstracts will not be published under Metabolism and will not be eligible for oral abstract presentations or awards.  In addition, upon acceptance of your encore abstract, at least one of the authors should be registered for the conference and is present on-site to present their posters during the meeting.
5. Abstracts must be submitted electronically and should not exceed 250 words. Tables, graphs, figures, or references should not be included.
6. All materials must arrive on or before the abstract deadline noted.
7. Authors may be listed on multiple abstracts.
8. Abstracts will be graded by the scientific planning committee, The International Committee for Insulin Resistance.
9. Poster guidelines, including presentation size and layout details, can be found at wcir.org/poster-guidelines.

Eligibility for Publishing: To be eligible for publishing, authors must be registered participants of the 22nd WCIRDC. If an author wishes to make changes or withdraw their abstract, they must notify the WCIRDC team no later than November 30, 2024. Requests submitted after this date may not be accommodated.

Special Notice:

All abstracts submitted are being checked for plagiarism. Of note, the software is able to identify plagiarism based on all international journals. Abstracts that will be identified as such, will not be published and the authors will be barred from future submission.  

For any inquiries or clarifications, please contact us at info@tmioa.com.

We are looking forward to your valuable contributions and the success of the 22nd WCIRDC.

9th Heart in Diabetes (HiD)  

Dates: June 6-8, 2025 

Deadline: May 1, 2025

• Accepted Abstracts will be published in American Heart Journal, Editor-in-Chief: Daniel Mark, MD, MPH
• Accepted Abstracts will have a poster presentation at the meeting.
• Top Abstracts will be selected for oral presentation at the meeting.
• Top 4 Abstracts will receive awards and cash prizes.

To be published in the American Heart Journal and to present a poster at the conference, the author(s) must register for the 9th annual Heart in Diabetes Conference. **

Encore abstracts are accepted under special circumstances. Make sure to identify your abstract as an encore if it was published or presented in a different conference. Please note that Encore abstracts will not be published under Metabolism and will not be eligible for oral abstract presentations or awards.  In addition, upon acceptance of your encore abstract, at least one of the authors should be registered for the conference and is present on-site to present their posters during the meeting.

Special Notice: All abstracts submitted are being checked for plagiarism. Of note, the software is able to identify plagiarism based on all international journals. Abstracts that will be identified as such, will not be published and the authors will be barred from future submission. 

Abstract Submission Topics

Abstracts should address state-of-the-art clinical research aspects of diabetes and the heart. (As an example, obesity by itself will NOT qualify, but obesity as it relates to diabetes and/or cardiovascular disease will qualify). 

Topics Include: diabetes, hypoglycemia, prediabetes, and/or cardiometabolic syndrome, retinopathy, obesity, neuropathy, dyslipidemia, triglycerides, cholesterol, hypertension, congestive heart failure (CHF), atherosclerosis, cardiovascular disease, arrhythmia, kidney/renal disease, cardiorenal syndrome, thrombosis, coagulation abnormalities, therapeutics, clinical trials, cardiovascular outcome trials, epidemiology, fatty liver, inflammation, guidelines on practice, technology, peripheral vascular disease, and related conditions. Although the posters are not designed for basic science, abstracts that consider unknown MOA (mode of action) of medications or pathophysiology of related medical conditions may be accepted.   

Abstract Poster Presentations

Abstracts may be submitted for poster presentation. If selected for poster presentation, the author(s) or presenter(s) are required to register for the Congress and to be present during the poster sessions. The presenter in attendance must be one of the authors listed in the abstract. 

Abstract Oral Presentations

Four of the highest-ranking abstracts will be selected for the Abstract Oral Presentation Session. In some cases, the committee may consider Late-Breaking Abstracts for oral presentation. The authors of the winning abstracts will present their research findings in a 10-minute presentation, followed by 5 minutes of Q&A. If selected, an author is required to register for the meeting and to be prepared with a PowerPoint presentation. Oral presenters who have an interest or involvement in selling a technology, program, product, and/or service to healthcare professionals must submit an official disclosure document to be considered for and to present their work at the abstract oral session.   ​  

Top Abstract Awards

Awards will be given to the highest-ranking abstracts. The award levels are: Gold, Silver, Bronze, and honorable mention.    

**Please note: If an author wishes to make changes or withdraw their abstract, they must contact our staff no later than May 31, 2025. HiD cannot guarantee that any change or withdrawal requests submitted after this date will be accommodated. Any requests should be submitted via e-mail to info@tmioa.com.

In addition:

• Abstracts and scientific materials presented at the 9th Annual Heart in Diabetes (2025) must not have been published or presented prior to June 06, 2025. 
• Encore abstracts are accepted under special circumstances, provided that upon selection at least one of the authors should be registered for the conference and is present on-site to present their posters during the meeting. Please note that Encore abstracts will not be published under the American Heart Journal and will not be eligible for oral abstract presentations or awards.
• All abstracts must be submitted electronically in Microsoft Word format and should be no more than 250 words (Titles, author(s) names, and affiliations are not included in the word count).
• Graphs or figures submitted must be in TIFF or JPG format.
• All materials must arrive on or before the abstract deadline noted above.
• Notification for acceptance will be e-mailed as soon as the committee accepts the abstract.
• Authorship on multiple abstracts is permitted.
• All submitted content will be graded by the 2025 Heart in Diabetes Scientific Abstract Committee.
• Abstracts will be published in an issue of the American Heart Journal. Click on the images to see a sample of the recently published works.  

The Abstract Poster Reception at the Exhibit Hall starts on Friday, June 6, from 6:15 pm to 7:15 pm. Early Poster Set-up will be available on Thursday, June 5, 2025, from 11:00 am to 6:00 pm. Please have your posters placed on your designated board before the day of the conference, as the Exhibit Hall opens on Friday, June 6, 2025, at 7:00 am.

Late Breaking Abstract Submission Deadline: May 6 - 22, 2025

• Accepted Abstracts will be published in American Heart Journal, Editor-in-Chief: Daniel Mark, MD, MPH
• Accepted Abstracts will have a poster presentation at the meeting.
• Top Abstracts will be selected for oral presentation at the meeting.
• Top 4 Abstracts will receive awards and cash prizes.

ePosters are due May 31, 2024.

 ePosters are PDF copies that will be displayed on our virtual platform.

The Abstract Oral Presentation is on Saturday, June 7 , 2025, starting at 8:00 pm to 9:00 pm.

The Oral Abstract Winner Award Presentation is on Sunday, June 8, 2024, at 8:00 am.

Important Notice:  "Make sure you include in all abstracts involving human or animal  studies state approval by ethics committees as well as authors’ affiliation in detail and country of origin."

Welcome!

We are delighted that you have accepted our invitation to participate in the 22nd annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Continuing Medical Education (CME) Conference. This conference is a live in-person event with a component of on-demand and will be held from December 12-14, 2024 at the Hilton Universal (555 Universal Hollywood Dr, Universal City, CA 91608). For more information, please visit our website at wcir.org

Honorarium as permissible, travel expenses, and suitable accommodations will be covered in accordance with government, sunshine act, and ACCME rules and guidelines. If you have any questions or need additional information please contact our office at (818) 342-1889 or email info@tmioa.com

We greatly appreciate your participation in this very exciting and important endeavor. Please proceed to provide all CME-required information. We look forward to having you be a part of the 21st WCIRDC in Los Angeles!

Best Regards,
WCIRDC Team